Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

29 Zoekresultaten.

Screening Visit 1 Psoriasis NCT02695940

- 27-09-21 - 1 Formulier, 10 Itemgroepen, 62 Data-elementen, 1 Taal

Itemgroepen: Administrative data, Eligibility criteria, Demography, Medical History, Treated body regions, Vital signs, ECG, Blood sample, Urine sample, miscellaneous

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Eligibility NCT00408187 Psoriasis - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 30 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00408187

Eligibility NCT00606450 Psoriasis - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 24 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00606450

Eligibility NCT01194219 Plaque Psoriasis - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 29 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT01194219

Eligibility NCT00245765 Chronic Plaque Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00245765

Eligibility NCT00329303 Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00329303

Eligibility NCT00852670 Plaque Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 7 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00852670

Eligibility NCT00574249 Chronic Plaque Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 2 Talen

Itemgroepen: Inclusion Criteria, Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00574249

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

- 15-06-21 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 1 Taal

Itemgroepen: Inclusion Criteria, Exclusion Criteria

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

PASI Psoriasis MIPSO EudraCT 2014-003022-40

- 11-06-18 - 1 Formulier, 2 Itemgroepen, 33 Data-elementen, 1 Taal

Itemgroepen: Use of the form, Psoriasis Area and Severity Index

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger PASI: Fredriksson T, Pettersson U: Severe psoria - sis – Oral therapy with a new retinoid. Dermatologica 178; 157: 238–244.

Visit 6 Psoriasis NCT02695940

- 22-01-18 - 1 Formulier, 8 Itemgroepen, 50 Data-elementen, 1 Taal

Itemgroepen: Administrative data, Medical History and physical exam, Vital signs, ECG, Blood sample, Urine sample, Picture, Signature

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Visit 5 Psoriasis NCT02695940

- 22-01-18 - 1 Formulier, 4 Itemgroepen, 25 Data-elementen, 1 Taal

Itemgroepen: Administrative data, Medical History, Medication, signature

NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.